COMP <GO>
ELMD vs JNJ // GROSS PROFIT MARGIN
Electromed Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ELMD 4
— JNJ 7
▲ GROSS PROFIT MARGIN LEADER: ELMD
LAST: $27.68 (+1.47%) • MKT CAP: $229.4M
gross-margins
78.10%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELMD VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELMD | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 78.10% | 67.90% | +10.20 | ELMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 24.10% | 25.50% | -1.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.8x | 18.5x | +3.30 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 4.85% | 2.97% | +1.88 | ELMD | /fcf-yield <GO> |
| Operating Margin | 15.10% | 34.70% | -19.60 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 11.80% | 28.50% | -16.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 17.00% | 6.00% | +11.00 | ELMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 17.64 | 5.59 | +12.05 | ELMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.8 | 62.1 | -13.30 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.5x | 23.0x | +2.50 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $229.4M | $662.49B | -$662.26B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELMD REV | JNJ REV | ELMD GROSS % | JNJ GROSS % | ELMD FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $64.0M | $94.19B | 78.1% | 67.9% | $11.1M | $19.70B |
| FY 2024 | $54.7M | $88.82B | 76.3% | 69.1% | $8.8M | $19.84B |
| FY 2023 | $48.1M | $85.16B | — | — | $1.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELMD // BETA —
JNJ // BETA 1.08